Snapshot
Guardant Health, Inc. reported $265M of revenue in Q3 2025, up 38.5% year over year, with diluted EPS of $-0.74 and an operating margin of -37.3%.
- Revenue
- $265M
- YoY growth
- +38.5%
- Diluted EPS
- $-0.74
- Operating margin
- -37.3%
$265M
Revenue
+38.5%
YoY growth
$-0.74
Diluted EPS
-37.3%
Operating margin
01 Key takeaways
What management said
- •Starting on slide three, Q3 was an exceptional quarter for Guardant Health, with broad-based growth across our business.
- •Technology volumes grew 40% as year-over-year volume growth continued to accelerate, driven by Guardant360 Liquid, Guardant360 Tissue, and Reveal.
- •Our biopharma business grew nicely year over year with positive CDx momentum, and screening volume accelerated with a sequential increase of 8,000 Shield tests.
- •Importantly, screening has started to generate meaningful revenue, tracking at an annual run rate of approximately $100 million, roughly one year into the commercial launch of the FDA-approved product.
- •Overall, we are very pleased with our performance this quarter, delivering 39% year-over-year revenue growth and crossing over $1 billion in annualized revenue for the first time.
- •Excluding screening, we reached a major milestone, with the rest of the business becoming cash flow positive one quarter earlier than expected.
- •Now turning to top-line performance in slide four, Q3 revenue grew 39% year over year to $265 million, with strong performance again across our oncology, screening, and biopharma and data businesses.
- •Taking a closer look at our oncology business on slide five, oncology revenue increased 31% to $184 million, and oncology volumes increased 40% year over year to approximately 74,000 tests in the third quarter.
- •In addition to Guardant360 Liquid, Guardant360 Tissue and Reveal volumes also experience strong year-over-year growth.
- •Looking more closely at some of the recent highlights within our oncology business on slide nine, Guardant360 volume grew exceptionally, with more than 30% year-over-year growth.
- •Turning to slide 10 to take a closer look at our Reveal data pipeline.
- •Turning now to slide 11, I'm proud of the progress we have made over the last few years in both driving demand and revenue growth across our portfolio.
SourcesCompany financials · earnings call
Last updated